Expired activity
Please go to the PowerPak homepage and select a course.

Flu Forum: Are You Ready for the 2020-2021 Season?

This continuing pharmacy education activity is provided by

This activity is supported by an educational grant from Genentech, Inc.


December 15, 2020


December 14, 2021

Target Audience

The intended audience for this activity is family practice physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Diagnose patients with influenza infection early by using evidence-based guidelines and best practices.
  • Select the most appropriate treatment for patients with influenza based on its safety, efficacy, and its ability to reduce complications in patients at normal or at high risk for complications.

Activity Co-Chairs

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA


Influenza places a substantial burden on the health of people in the United States each year, with varying impact. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, and between 12,000 and 61,000 deaths annually since 2010. Primary care providers, nurse practitioners, physician assistants, pharmacists, and other health care professionals can identify and help manage influenza in the community. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Clinicians who evaluate patients must keep apprised of new information regarding the diagnosis and treatment of influenza so they can incorporate this information into practice, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes (although adamantanes are not recommended for use in the United States), and the polymerase inhibitor, baloxavir marboxil. “Flu Forum: Are You Ready for the 2020-2021 Season?” explores strategies for early diagnosis of influenza using evidence-based guidelines as well as selection of the most appropriate treatment of influenza, based on its safety, efficacy, and its ability to reduce complications in patients at normal or at high risk. Clinical cases are also presented to highlight the key educational objectives.


acpeVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

This program is acceptable for 1.00 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-20-020-H01-P, effective 12/15/2020. This is a knowledge-based activity, and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, December 15, 2020, to December 14, 2021.

How to Participate in This Activity and Obtain Credit

During the period December 15, 2020, to December 14, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) complete the pre-survey; 3) study the educational activity; and 4) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. You must answer 4 out of 5 posttest questions correctly to achieve a passing score. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  Your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Co-Chairs report the following relationships

Paul G. Auwaerter, MD, MBA, FIDSA
Consulting Fee: Advanced Biotherapeutics, DiaSorin
Ownership Interest: Johnson & Johnson

John J. Russell, MD, FAAFP
Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewers report the following relationships

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario Jr., MD
No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
No relevant financial relationships to disclose.

Marilyn N. Bulloch, PharmD, BCPS, FCCM
Speakers Bureau: Genentech

Vindico Medical Education staff have no relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com